Evidence map›Paper›PMID 30013318›Full record

ReviewDrug design, development and therapy2018

Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy.

Mihaela Popescu, Cătălina Bogdan, Adela Pintea, Dumitriţa Rugină, Corina Ionescu

Open access · goldAbstract readReview
In one paragraph

Review in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Polyphenol Metabolite Pyrogallol-International journal of molecular sciences · 2021
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mihaela PopescuDepartment of Biochemistry, University of Medicine and Pharmacy "Iuliu Haţieganu", Cluj-Napoca, Romania.
Cătălina BogdanDepartment of Dermopharmacy and Cosmetics, University of Medicine and Pharmacy "Iuliu Haţieganu", Cluj-Napoca, Romania, catalina.bogdan@umfcluj.ro.
Adela PinteaDepartment of Biochemistry, University of Agriculture Sciences and Veterinary Medicine, Cluj-Napoca, Romania.
Dumitriţa RuginăDepartment of Biochemistry, University of Agriculture Sciences and Veterinary Medicine, Cluj-Napoca, Romania.
Corina IonescuDepartment of Biochemistry, University of Medicine and Pharmacy "Iuliu Haţieganu", Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy · ROUniversity of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) affects >350 million people worldwide. With many complications that can reduce the patient's quality of life, vision loss is one of the most debilitating disorders it can cause. Active research in the field of diabetes includes microvascular complications in diabetic retinopathy (DR). Disturbances in the balance of pro-angiogenesis and anti-angiogenesis factors can lead to the progression of DR. The retinal pigment epithelium (RPE) is the outermost layer of the retina, and it is essential in maintaining the visual function. The RPE produces and secretes growth factors as well as protective agents which maintain structural integrity of the retina. Small natural molecules, such as resveratrol, may influence neurotrophic factors of the retina. The pigment epithelium-derived factor (PEDF) and thrombospondin-1 (TSP-1) are secreted by RPE cells. These two proteins inhibit angiogenesis and inflammation in RPE cells. An alteration of their production contributes to various eye diseases. There is a critical balance between two important factors secreted on opposite sides of the RPE: at the basal side, vascular endothelial growth factor (VEGF; acts on the choroidal endothelium) and, on the apical side, PEDF (acts on neurons and photoreceptors). Resveratrol inhibits VEGF expression in human adult RPE cells and limits the development of proliferative vitreoretinopathy, by attenuating transforming growth factor-β2-induced wound closure and cell migration. Possible new mechanisms could include PEDF and TSP-1 expression alterations under physiological and pathological conditions. Resveratrol is currently of interest due to its capacity to influence the cell's secretory activity. Some limitations arise from its low bioavailability. Several drug delivery systems are currently tested, promising to improve tissue concentrations. This article reviews biological pathways involved in the pathogenesis of DR that could be influenced by resveratrol. A study of these pathways could identify new potential targets for the reduction of diabetic complications.

Indexed as

Angiogenesis InhibitorsAnimalsCytokinesDiabetic RetinopathyHumansNeovascularization, PathologicResveratrolRetinal Pigment EpitheliumAngiogenesis InhibitorsCytokinesResveratroldiabetesdiabetic microvascular complicationsphytoalexinretinal secretome

Identifiers

PMID30013318
PMCPMC6037275
OpenAlexW2810265309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.